Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W K Kelly

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2000
The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancerW K Kelly, I Osman, V E Reuter, et al.
Seminars in Oncology|December 1, 1996
Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approachS F Slovin, P O Livingston, N Rosen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2009
Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trialsM M Regan, E K O'Donnell, W K Kelly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1997
Bicalutamide for advanced prostate cancer: the natural versus treated history of diseaseH I Scher, C Liebertz, W K Kelly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1995
Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implicationsR A Ghossein, H I Scher, W L Gerald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1995
Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancerW K Kelly, H I Scher, M Mazumdar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2000
Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancerE J Small, M W Frohlich, R Bok, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trialD F Bajorin, J A McCaffrey, S Hilton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinomaJ A McCaffrey, S Hilton, M Mazumdar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2000
Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancerM J Zelefsky, W K Kelly, H I Scher, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2000
The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancerW K Kelly, I Osman, V E Reuter, et al.
Seminars in Oncology|December 1, 1996
Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approachS F Slovin, P O Livingston, N Rosen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2009
Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trialsM M Regan, E K O'Donnell, W K Kelly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1997
Bicalutamide for advanced prostate cancer: the natural versus treated history of diseaseH I Scher, C Liebertz, W K Kelly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1995
Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implicationsR A Ghossein, H I Scher, W L Gerald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1995
Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancerW K Kelly, H I Scher, M Mazumdar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2000
Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancerE J Small, M W Frohlich, R Bok, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trialD F Bajorin, J A McCaffrey, S Hilton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinomaJ A McCaffrey, S Hilton, M Mazumdar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2000
Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancerM J Zelefsky, W K Kelly, H I Scher, et al.
Pageof 4